Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. - Wikidata - thesis-toulmin - TriplyDB

Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.

Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.

http://www.wikidata.org/entity/Q38206050

about

Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View Pathogenesis of minimal change nephrotic syndrome: an immunological concept Treatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two Decades Immunologic Changes Implicated in the Pathogenesis of Focal Segmental Glomerulosclerosis Cost-Effectiveness of Administering Rituximab for Steroid-Dependent Nephrotic Syndrome and Frequently Relapsing Nephrotic Syndrome: A Preliminary Study in Japan.The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis Cyclic nucleotide signalling in kidney fibrosis.Circulating CD40 autoantibody and suPAR synergy drives glomerular injury.Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.Causes and pathogenesis of focal segmental glomerulosclerosis.Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment.Infectious complications of rituximab therapy in renal disease.Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease.Synaptopodin is upregulated by IL-13 in eosinophilic esophagitis and regulates esophageal epithelial cell motility and barrier integrity.Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis.Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes.Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.Adult minimal-change disease: observational data from a UK centre on patient characteristics, therapies, and outcomes

P2860

Q26738374-A2755A50-2106-4F51-A77A-AC22658635AB Q26747387-FA7307A5-074A-45A2-833B-44FE7E45B0E3 Q26752836-D1DACD9B-83EA-4197-B67A-F2F4097D4EDF Q26753833-08197B5A-9D37-44D4-829C-76151826B306 Q30844502-BD26F3B7-4878-420F-8028-91182DDDB85F Q35040896-2421548A-F51D-401B-B5CB-4ED982E60D05 Q35138860-0482A7BD-C5FB-4578-853D-FA2BF2F191B3 Q36352504-61663AAA-F369-4013-AECC-184B70FF2C35 Q36987307-9C59A5B4-4EDF-4192-8B36-D2FEFD18F5C0 Q37261621-31053A55-5BA5-4D65-A9DF-249C570FC468 Q38275115-D4BE76FC-D1E5-489D-A782-FEC823F0FE79 Q38679589-5981B021-74F8-4CEA-AAA3-E615DFCB782A Q38854254-ED2EDCD9-F05F-4285-8216-36F6606D6D17 Q40065728-5F9722F8-38AF-4AA9-A320-3BDE387B09D6 Q40075357-1977022D-77D6-47E2-BC2C-C66BE66D4E4F Q42517074-7A419F26-7B33-45BF-B374-986167F431D0 Q47147627-C9523F3F-66FE-4C36-9468-93AE796122A2 Q53637511-43FD7F3E-F316-4F52-8F46-C1174CC7936B Q53838634-A315F3D3-09C3-4320-B837-5675ED2E70F0 Q56888597-3D82FB2C-4C2F-41F1-9F80-2C2979B785C6

P2860

Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.

http://www.wikidata.org/entity/Q38206050

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Rituximab treatment for relaps ...... clerosis: a systematic review.

@en

type

label

Rituximab treatment for relaps ...... clerosis: a systematic review.

@en

prefLabel

Rituximab treatment for relaps ...... clerosis: a systematic review.

@en

P1433

Q38206050-32F96F26-F7A9-4561-989A-FD2470C3593B

P1476

Q38206050-EF1BCDA2-3459-45EA-8CF6-6A95FAB8807D

P2093

Q38206050-3B8A278D-1B2C-49E3-9BC7-DAE75555662D

Q38206050-68A636E3-9951-4C37-A381-EA044C9D6A56

Q38206050-CB161ED3-0EB3-4703-B035-EDECD17C056B

Q38206050-D2720BCC-BF42-4D9A-BCEA-95290AF1FF84

Q38206050-D7AD72B6-454C-4676-AD63-36692D1C2C1D

Q38206050-F14CE6AB-7F45-482C-9DB8-AE01207E3CDF

P2860

Q38206050-04F1385A-23F8-4905-A6F0-7E4D68143A7A

Q38206050-2C4AE3D8-6677-4932-B1EE-9D0A42F00D82

Q38206050-35311581-833A-480E-85A4-417D5C8B045C

Q38206050-370C6644-1E03-42E5-96C8-A6A31CDFACB2

Q38206050-39E6BA27-67BB-4FD7-BE12-B1C174D1A9ED

Q38206050-4A1A9B5C-C846-415B-8D5A-575E6B9EFE56

Q38206050-4C135CEA-9E80-4522-95B2-26AF8A7918C3

Q38206050-4CA5A3CE-21F9-4D47-B4FB-477FD96BEF1A

Q38206050-54C00C75-07AD-4C17-9DC8-08B8FD16E532

Q38206050-58307F29-2A5C-4014-B1D2-B2C91D346970

P304

Q38206050-277380D3-1C5C-4077-A6AF-87DF1FE30973

P31

Q38206050-2A945F1F-4C1C-4FE4-AB55-929E01BCD1CF

P356

Q38206050-ABEFC8AF-797B-4027-B7C5-481C47E7D53C

P433

Q38206050-1EB2DD6C-3333-40A5-A5C1-DC9843E56728

P478

Q38206050-2181A10A-ADD1-4594-9202-AD7BF9DDD19A

P50

Q38206050-31C42B56-0FDA-4B70-960D-9D5D462B31C2

Q38206050-9F82C09D-1164-47D5-8C0F-7F80A376CE06

Q38206050-AD4B9A28-5310-40F0-8652-34179E2CFD8C

P577

Q38206050-26C6EA76-B9E5-47E5-84A8-05A42324CE88

P5875

Q38206050-DBCE30EA-A206-4097-95CE-55A620ADF19C

P698

Q38206050-4CD4B918-0EE0-4AFD-91AC-30B34A85D87E

P356

P1433

American Journal of Nephrology

P1476

Rituximab treatment for relaps ...... sclerosis: a systematic review

@en

P2093

Christine E Kurschat

http://www.w3.org/2001/XMLSchema#string

Elion Hoxha

http://www.w3.org/2001/XMLSchema#string

Gema Fernandez-Fresnedo

http://www.w3.org/2001/XMLSchema#string

Julia Kerschbaum

http://www.w3.org/2001/XMLSchema#string

Martin Busch

http://www.w3.org/2001/XMLSchema#string

Michael Rudnicki

http://www.w3.org/2001/XMLSchema#string

P2860

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission.

Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.

Prevention and treatment of systemic glucocorticoid side effects.

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.

Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants.

Renal involvement in autoimmune connective tissue diseases.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Clinical trial of focal segmental glomerulosclerosis in children and young adults.

P304

322-330

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000360908

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Kronbichler

Annette Bruchfeld

P577

2014-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261769869

http://www.w3.org/2001/XMLSchema#string

P698

24751753

http://www.w3.org/2001/XMLSchema#string